Viewing Study NCT00431795


Ignite Creation Date: 2025-12-24 @ 2:17 PM
Ignite Modification Date: 2026-01-02 @ 5:32 AM
Study NCT ID: NCT00431795
Status: TERMINATED
Last Update Posted: 2013-02-13
First Post: 2007-02-05
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer
Sponsor: Hellenic Oncology Research Group
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Advanced breast cancer View
None Pegylated liposomal doxorubicin View
None Epirubicin View